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Abstract 
Objective: To derive new criteria sets for defining manic and hypomanic episodes (and thus 
for defining the bipolar I and II disorders) an international Task Force was assembled and 
termed AREDOC reflecting its role of Assessment, Revision and Evaluation of DSM and 
other Operational Criteria. This paper reports on the first phase of its deliberations and 
interim criteria recommendations.  
Method: The first stage of the process consisted of reviewing DSM-5 and recent ICD 
criteria, identifying their limitations and generating modified criteria sets for further in-depth 
consideration. Task Force members responded to recommendations for modifying criteria 
and from these the most problematic issues were identified. 
Results: Principal issues focussed on by Task Force members were how best to differentiate 
mania and hypomania, how to judge ‘impairment’ (both in and of itself and allowing that 
functioning may sometimes improve during hypomanic episodes) and concern that rejecting 
some criteria (e.g. an imposed duration period) might risk false positive diagnoses of the 
bipolar disorders. 
Conclusion: This first-stage report summarises the clinical opinions of international experts 
in the diagnosis and management of the bipolar disorders, allowing readers to contemplate 
diagnostic parameters that may influence their clinical decisions. The findings meaningfully 
inform subsequent Task Force stages (involving a further commentary stage followed by an 
empirical study) that are expected to generate improved symptom criteria for diagnosing the 
bipolar I and II disorders with greater precision, and to clarify whether they differ 
dimensionally or categorically. 
 
Keywords: Bipolar disorder; diagnosis; mania; hypomania; DSM-5 
 
 
 
 
Introduction 
The status and definition of the bipolar disorders and of mixed states have been issues 
extensively considered in this journal in recent years (Berk et al., 2005; Fletcher et al., 2018; 
Ghaemi and Dalley, 2014; Kuiper et al., 2012; Malhi and Berk, 2014; Malhi et al., 2016a; 
Malhi et al., 2016b; Malhi et al., 2018), with the valid differentiation of the bipolar sub-types 
of particular concern. Such detailed considerations reflect to some degree issues with the 
DSM-5 and recent ICD classifications of the bipolar disorders, with both inviting challenges 
concerning the extent to which they validly distinguish mania and hypomania, and thus 
bipolar I (BP I) disorder and bipolar II (BP II) disorder. 
 As a consequence of such concerns, the AREDOC (Assessment, Revision and 
Evaluation of DSM and other Operational Criteria) Task Force of international experts on the 
bipolar disorders was formed to review and iteratively develop a set of revised criteria and, 
after testing them empirically, finalise their structure. If valid, the revised criteria should 
facilitate research into whether the bipolar disorders differ dimensionally (i.e. simply by 
severity) or categorically, and whether they show differential responses to specific 
medications. 
We first overview DSM-5 decision rules and their limitations. A DSM-5 diagnosis of 
a BP I disorder requires the individual to meet criteria for a current or past manic episode 
(which may oscillate with hypomanic or major depressive episodes) while a diagnosis of BP 
II disorder requires meeting criteria for a current or past hypomanic (but never manic) 
episode and a current or past major depressive episode. The diagnostic criteria for both 
disorders therefore weight lifetime features. As the distinction between mania and hypomania 
effectively defines the distinction between BP I disorder and BP II disorder, we firstfocus 
here on how manic and hypomanic episodes are defined and differentiated in DSM-5.  
 DSM-5 Criteria A and B are very similar for manic and hypomanic episodes. 
Criterion A (a global descriptor) for manic and hypomanic episodes is virtually identical 
except for a difference in duration (i.e. at least four consecutive days for hypomania and one 
week for mania) but allows any duration for mania (i.e. briefer than one week) if the 
individual is hospitalised, and with an addition of ‘goal-directed’ preceding reference to 
activity and energy for manic (but not hypomanic) episodes. Specifically, this criterion 
requires “A distinct period of abnormally and persistent elevated, expansive, or irritable 
mood and abnormally and persistently increased (goal-directed) activity or energy,” and 
lasting respectively at least 4 consecutive days as against 1 week for hypomania and mania 
(or any duration for mania if the patient is hospitalised)….“and present most of the day nearly 
every day.” Thus, Criterion A differences between manic and hypomanic episodes are slight, 
while Criterion B lists an identical set of symptoms for mania and for hypomania and 
imposes the same cut-off in symptom numbers, thus effecting no differentiation at all.  
Differentiation between manic and hypomanic episodes predominantly arises from the 
criteria addressing occupational functioning and hospitalisation. Criterion C for mania states 
that impairment in social or occupational functioning must be “marked,” while Criterion E 
for hypomania states it is “not severe enough” to “cause marked impairment.” Criterion D for 
a hypomanic episode requires the individual’s unequivocal change in functioning to be 
observable by others, while there is no equivalent observational criterion for a manic episode. 
An episode is assigned as manic (and therefore bipolar I status is accorded) if the individual 
is hospitalised or if there are psychotic features present. While the latter appears categorical 
(and thus implying that they are sufficient but not necessary to the definition of mania), it is 
contradicted by two later specifiers (p. 135) for BP II disorder, which allow individuals to 
have either mood-congruent or mood-incongruent psychotic features in relation to hypomanic 
as well as to depressive episodes. Thus, there are only two absolute points of differentiation 
between DSM-5-defined manic and hypomanic episodes: if the patient is hospitalised, and/or 
if there is marked social or occupational impairment, then the mood episode is designated as 
manic in type.   
Since the early descriptions of manic-depressive illness, its conceptualisation as a 
psychotic disorder has persisted with few challenges. For hypomania, its history is briefer and 
its status less clear. Mendel (1881) was one of the first to define the concept as expressed by 
elevated mood, pressured speech and increased motor activity, and with all such features 
consistent with mania but to a lesser degree – with this description essentially positioning 
mania and hypomania dimensionally and according to the level of severity of mood 
elevations. Early in the twentieth century cyclothymia and hypomania were categorised as 
“milder forms of the manic-depressive psychosis” (Buzzard et al., 1930), but the concept of 
hypomania or a “milder” form of bipolar disorder effectively disappeared from the literature 
until Dunner et al. (1976, 2017) described a (BP II disorder) group whose members were “in 
between” BP I patients and unipolar major depressive disorder patients. DSM-III 
subsequently formally introduced the concept of BP II disorder for the first time (albeit titled 
‘Atypical Bipolar Disorder”) and briefly described as “an episode of illness with some manic 
features (hypomanic episode) but not of sufficient severity and duration to meet the criteria 
for a manic episode.” While defining hypomanic episodes (but not a BP II condition), DSM-
III-R simply stated that its features were similar to those of a manic episode except that 
delusions were never present during highs and that other symptoms tended to be less severe 
than for mania. 
While multiple authors have continued to position hypomania as a ‘milder’ form of 
mania, some have argued for the respective presence or absence of psychotic features as 
defining and differentiating BP I disorder and BP II disorder elevated mood states. In one 
empirical study (Parker et al., 2016) of 1,081 patients clinically diagnosed with a bipolar 
disorder, a mixture analysis of core symptoms across two sub-populations showed a bimodal 
distribution (indicative of two separate ‘types’) and with psychotic features over-represented 
in those in the group scoring highest in symptom severity. The suggested centrality of 
psychotic features to mania and their absence in hypomanic states is consistent with several 
previous studies (e.g. Vieta et al., 1997). Thus, automatic assignment of bipolar disorder 
patients experiencing psychotic features with an elevated mood to receive a DSM-5 diagnosis 
of mania is likely to be valid (although, as noted, this decision is confounded by DSM-5 
specifers allowing psychotic features to be present in hypomania).  
The ‘absolute’ DSM-5 criterion whereby hospitalisation generates automatic 
assignment to manic status invites criticism on the grounds of reality and logic. Specifically, 
while hospitalisation may be a marker of severity, there are many regions in the world 
lacking psychiatric hospitals, while thresholds for hospital admission vary across treatment 
settings based on issues of access, availability and other resources. In terms of logic, we are 
unaware of any other psychiatric (or medical) condition that includes hospital admission as a 
diagnostic criterion. It also fails to capture the reality that some bipolar patients with 
hypomanic episodes may still require admission to protect their reputation, prevent risk-
taking behaviour or manage their hypomanic state. For instance, in an Australian study 
(Parker and Graham, 2017) examining admissions to psychiatric hospitals from 2000 until 
2014 (inclusive), there were 2,882 admissions for those with ICD-10 diagnosed mania and 
5,373 for those with ICD-10 diagnosed hypomania. It therefore appears that hospitalisation is 
not restricted to those experiencing manic (as opposed to hypomanic) episodes unless 
hospitalisation becomes the defining criterion. Thus, if mania is to be distinguished from 
hypomania by severity as a criterion (which would seem logical) then it would be preferable 
to avoid using hospitalisation as a proxy for severity and instead define levels of severity for 
the two conditions more directly. 
The other absolute DSM-5 criterion for assignment of mania as against hypomania 
status (i.e. functional impairment) also invites criticism. As noted earlier, the definitions 
require “marked impairment” for mania, while, for hypomania the episode is “not severe 
enough to cause marked impairment.” Such differentiation presents two issues: Firstly, how 
can the level of impairment in social and occupational functioning be validly judged when it 
relies on subjective judgment by the patient and/or assessing clinician in the absence of 
clearly established thresholds? Secondly, this criterion fails to recognise that some 
individuals actually report (and demonstrate) improved social and occupational functioning 
and an increase in creativity when hypomanic. Thus, if an individual experiencing a 
hypo/manic episode has not been hospitalised, the only differentiating criterion to assign 
manic versus hypomanic (and thus BP I or BP II disorder) status is the degree of impairment, 
and with assessment of that criterion being limited by its intrinsic subjectivity and its variable 
presence. 
Turning to duration criteria, DSM-III imposed a minimum duration of one week for a 
manic episode. However, lacking any formal BP II disorder, the manual effectively assigned 
an “atypical bipolar disorder” diagnosis to those who experienced a hypomanic episode 
which was not of “sufficient severity and duration to meet the criteria for a manic episode” 
(p. 223), and thus did not impose any minimum duration for hypomanic episodes. DSM-III-R 
did not include a duration criterion for mania but stated in the general text (p. 216) that 
episodes “usually last from a few days to months.” Thus, while DSM-III-R allowed brief 
durations for manic episodes it did not position duration as integral to the definition of 
hypomania. DSM-IV imposed the minimum duration periods for mania and hypomania (i.e., 
7 and 4 days, respectively, unless those with mania are hospitalised) preserved in DSM-5. 
Such minimum periods have been challenged in relation to their validity. In a Zurich 
community study of those identified with BP II disorder, Angst (1998) compared subjects 
meeting DSM hypomania duration of four or more days with those having episodes lasting 1-
3 days and found similar symptom profiles across 15 hypo/manic items. Several subsequent 
studies (e.g. Bauer et al., 2011; Benazzi and Akiskal, 2006; Judd et al., 2003; Parker et al., 
2014; Tully and Parker, 2007) demonstrated that hypomanic states (in those diagnosed with 
BP II disorder) lasting less than four days did not differ phenotypically from those lasting 
four or more days. In another study of 49 clinically diagnosed BP I patients and 52 BP II 
patients (Parker et al., 2006), it was established that, in relation to their longest ever 
hypo/manic episode, 45.8% of the BP I patients had never had an episode lasting as long as a 
week, and 43.7% of the BP II patients had never had an episode lasting longer than two days. 
Such studies are often discounted on the basis that, as subjects did not meet DSM duration 
criteria, their alternate defining criteria might also be invalid. However, their data (generally 
respecting DSM criteria other than duration) do suggest that current DSM duration criteria 
are problematic because, if an individual experiences a stereotypic hypo/manic episode that 
lasts less than the DSM-5 mandated duration (and which would appear to occur commonly), 
they cannot be diagnosed with either a BP I or BP II condition and may hence be 
inappropriately diagnosed and treated. 
 ICD-10’s criterion A did differ in defining hypomania and mania dimensionally - with 
mania having a higher level of severity, but also with manic episodes sub-classified as with or 
without psychotic features. Thus, psychotic features did assign a manic diagnosis, while the 
absence of psychotic features was a criterion for hypomania but also allowed for mania. 
Hypomania was defined as “a lesser degree of mania,” and lasting “at least several days,” 
while episodes of mania “should last for at least 1 week.” ICD-10’s symptom sets did differ 
slightly for hypomania and for mania with or without psychosis, while hospitalisation did not 
automatically assign manic status and there was no impairment criterion. ‘Bipolar affective 
disorder’ was subtyped on the basis of the current episode being hypomanic, manic without 
psychotic features, manic with psychotic features, mild or moderate depression, severe 
depression without psychotic features, severe depression with psychotic features or ‘mixed.’ 
Then, among the category of “other bipolar affective disorders” BP II disorder was listed 
(without any description or criteria) and without any preceding reference to any BP I 
disorder.  
 ICD-11 criteria allow several expressions of BP I disorder (e.g. current episode manic 
with or without psychotic features or evidencing hypomanic features), and allow that it may 
be diagnosed after a single manic or mixed episode but usually oscillates with depressive 
episodes. A manic episode is differentiated from a hypomanic episode by a longer duration of 
seven versus “several” days, with psychotic features allowable in manic but not hypomanic 
states, and with the former described as an “extreme mood state” and the latter as a 
“persistent mood state”, which are seemingly unaligned parameters. Each condition is 
described by sets of representative features with manic ones being more severe than the 
“mild” elevations of mood or increased irritability and activity integral to hypomanic states. 
ICD-11 defines BP II disorder as requiring one or more hypomanic episode - involving a 
number of symptoms lasting for at least “several days,” and not being severe enough “to 
cause marked impairment” or to necessitate hospitalisation – and at least one depressive 
episode. The manual also lists a number of patterns and features associated with depressive 
episodes for both the BP I and BP II disorders (e.g. psychotic symptoms or not, being of mild 
versus severe versus unspecified severity, as well as mixed states with or without psychotic 
symptoms). 
The ICD-11 system is in contrast with DSM-5 in building depressive features into the 
primary definition of the bipolar disorders, providing sets of representative symptoms rather 
than criteria sets, and imposing no cut-offs in symptom numbers. Its most distinctive change 
from ICD-10 is the provision of a more detailed definition of BP II disorder as a separate 
condition and in providing criteria for its diagnosis. Some of its decision rules (e.g. minimum 
duration criteria, and use of ‘marked impairment’ and hospitalization as points of diagnostic 
distinction) have been critiqued in relation to the earlier overview of DSM-5. 
We therefore judge that there are limitations to the current DSM and ICD criteria for 
differentiating mania from hypomania (and therefore BP I disorder from BP II disorder). 
Such concerns led to establishing the AREDOC Task Force with the objective of deriving a 
new set of criteria for better distinguishing manic and hypomanic episodes (and thus the BP I 
and BP II disorders) – whether dimensionally or categorically – that would address the issues 
overviewed here. This paper reports on the first stage of the revisional task, which sought to 
build on the DSM-5 template. 
Method 
An invitation and questionnaire were sent to an international group of mental health 
professionals recognised as having clinical and/or research expertise in the bipolar disorders. 
The questionnaire (which sought to weight the DSM-5 template) included current DSM 
criteria for mania and hypomania followed by amendments to those criteria as proposed by 
the first author (GP). The respondents were asked if they agreed with the proposed 
amendments and to offer any other modifications based on their clinical experience and 
research expertise. Amendments were generated in response to the questionnaire and in 
comments provided by members in preparing the current paper. 
Results  
Of the 123 professionals invited, 71 (57.7%) accepted and 63 (51.2%) responded to the first 
questionnaire thus making up a Task Force of 64 individuals from 14 countries spanning five 
continents.  
The DSM-5 Criterion A was modified with the proposed questionnaire definition for 
both a hypomanic or manic comprising: “A distinct period of abnormal and persistently 
elevated, expansive, or irritable mood, with the individual feeling energised and ‘wired,’ and 
which is perceived as an ‘overshoot’ and not simply a state of happiness, and generally 
oscillating with periods of depression.” The new definition builds on the DSM-5 criterion, 
captures the bipolar nature of the underlying condition (i.e. hypo/manic episodes oscillate 
with depressive periods), allows that individuals may have hypo/manic episodes before any 
depressive ones, seeks to address concerns about false positive diagnoses of bipolar disorder 
but imposes no duration criterion (with this issue considered later). 
 In response, 16 Task Force members were in total agreement with the proposed 
definition. Nineteen were against including any reference to such states oscillating with 
periods of depression, with most suggesting that reference to depression would be better 
included in a general background description of the bipolar disorders and their longitudinal 
course. The reference to depression was therefore removed. Eight were against any reference 
to ‘happiness,’ and this judgment was respected as superior wordings were offered by several 
members. Eight were against the ‘wired’ descriptor (either judging it as being too colloquial, 
not relevant across differing cultures or as redundant in light of the ‘energised’ descriptor). 
As seven were in favour of ‘wired,’ with one noting that it went to the ‘heart’ of a 
hypo/manic state and one that it was important in capturing the sufferer’s own subjective 
experience rather than the judgment of a clinician rater, it was retained for later empirical 
testing. 
 A few respondents offered comments about the ‘irritable’ descriptor. Three favoured 
its rejection, judging that it is not associated with hypo/mania, while three argued for its 
retention in light of some bipolar patients only having irritable moods and never being elated. 
As a number of studies (see Graham et al., 2015) have demonstrated an ‘irritable’ or 
‘irritable-racing thoughts’ factor as well as a contrasting ‘euphoric’ and ‘dysphoric’ 
hypo/manic phenotype, ‘irritable’ was retained but enriched with the suggested descriptor 
‘quick-tempered’ being added. Seven were against ‘overshoot’, either viewing it as colloquial 
or redundant. One favoured an ‘overshoot’ synonym such as “unambiguous departure from 
one’s normal or usual state”. It was removed to respect the majority vote. Only two voted 
against use of the word ‘abnormal’ on the basis of its pejorative tone, with one of those 
favouring ‘unusual’ as an alternative. In other sections of the questionnaire, several members 
emphasised hypo/manic states as being ‘abnormal,’ in the sense that both are (by definition) 
psychopathological and also distinct from ‘normal happiness-like’ states. Thus, ‘abnormal’ 
was retained. Several were against ‘perceived,’ noting that the individual may not have 
insight, and thus this word was removed. In relation to whether ‘impairment’ should be 
retained or deleted, more argued for reframing this component as a ‘functioning’ construct. 
So ‘change in functioning’ was substituted. 
 Thus, the new Criterion A for hypo/mania for later evaluation was: “A distinct period 
of either an abnormally elevated and expansive mood, or an irritable and quick-tempered 
mood, characterised by increased activity and cognition such that the individual feels 
unusually energised, ‘hyper’ or ‘wired’. Such changes are perceived at the time or on later 
reflection as excessive and an unambiguous change in functioning from the individual’s usual 
state.” 
DSM-5 Criterion B lists seven symptoms although several might be better viewed as 
broad constructs (e.g., increase in goal-directed activity). Task Force members were given a 
set of narrow symptoms and broad symptom constructs (including all DSM-5 criteria) for 
editorial revision as listed in Table 1. Two expressed concerns about non-specificity of some 
items, one argued for the need to have items that did not detect personality disorders, one 
recommended breaking down the at-risk activities into separate items, while several 
expressed the opposite concern of items having multiple and possibly overlapping constructs 
rather than a single one and the risk of moving into minutiae territory, and therefore some 
argued for a ‘lean and mean’ list. Some were concerned about the inclusion of delusions and 
hallucinations. 
    (Table 1 about here) 
Members were also invited to contribute items that they had observed as capturing 
nuances of hypo/manic states, whether phenotypically ‘happy’ or ‘snappy’. Based on such 
feedback the original set of 27 items was reworked to remove overlapping items as well as 
accommodate editorial suggestions, and so generated the new list of 92 items (listed in Table 
1). The concern about having too many items will be addressed at the empirical stage when 
we will have bipolar (and unipolar) subjects complete a self-report list of all candidate items. 
This will allow frequency estimates for all items to be calculated and their differential profile 
across BP I disorder, BP II disorder and unipolar states quantified, and those deleted if 
demonstrating low prevalence or differentiation rates – although we acknowledge that 
‘snappy’ bipolar states will generate low prevalence estimates in the whole sample (reflecting 
the lower prevalence of the irritable phenotype). Highly correlated items will be consolidated 
into ‘construct’ items, and optimal cut-off numbers needed for defining hypomania and 
mania derived. Thus, rather than the current DSM-5 model of having the same symptom 
criterion sets and same cut-off criteria for hypomania and mania, we anticipate analyses 
generating a set of shared obligatory symptoms for both hypomania and mania as well as 
facultative ones that differ (categorically or dimensionally) across the bipolar subtypes, while 
the cut-off criteria numbers for hypomania and mania are likely to differ. 
DSM-5’s Criterion C for hypomania alone (“The episode is associated with an 
unequivocal change in functioning that is uncharacteristic of the individual when not 
symptomatic”) was modified to include an observational component which incorporated 
DSM-5’s Criterion D for hypomania (that the mood and disturbance and change in 
functioning were “observable by others”) but with the criterion for both hypomania and 
mania allowing that such changes might only be observed by the individual and not 
necessarily by others. In response, 29 members supported this definition. Two noted that 
some individuals actually function better in such states (an issue addressed earlier and in 
more detail shortly), and 16 expressed concern about the risk of allowing subjectively 
experienced states alone to be accorded hypo/manic status and that true hypo/manic states 
should be observable by others. However, as a number of hypomanic individuals providing 
clear-cut symptoms have close relatives who fail to observe and confirm symptoms of 
hypomania, requiring such states to be observable by others would limit the diagnosis to only 
those individuals who have witnesses who actually observe such episodes. Thus, the 
allowance of observation of hypo/mania by the individual was retained and the new criterion 
for manic as well as for hypomanic states for later consideration became: “The episode is 
associated with an unequivocal change in functioning (as judged by the individual and/or 
observers) that is uncharacteristic of the individual when not symptomatic”. 
As noted, DSM-5’s Criterion C for a manic episode includes a ‘marked impairment’ 
requirement while DSM-5’s Criterion E for a hypomanic episode requires that the “episode is 
not severe enough to cause marked impairment in social or occupational functioning.” It was 
put to Task Force members that there should be no impairment requirement in light of (a) 
impairment being hard to judge, (b) the presence or absence of ‘marked’ (versus ‘less 
marked’) impairment also being hard to judge and (c) in many hypomanic states and 
occasionally in manic states, social or occupational functioning can be enhanced rather than 
compromised. The latter often self-reported observation has been supported empirically.  For 
instance, both Jamison et al. (1980) and Judd et al. (2005) found that a sub-set of patients 
reported improved functioning while hypomanic, and with the second study finding improved 
social functioning in the BP II disorder but not the BP I disorder sub-set, a finding with 
distinct implications.  
In response, 34 argued for retaining an impaired functioning criterion (as against 17 
for its deletion), principally judging that its removal could lead to overdiagnosis. Many felt 
that it was central to defining mania, while for hypomania several also acknowledged that 
functioning might be unaffected or improved (and thus should be used to so distinguish the 
two conditions). The observation that functioning might actually be improved caused several 
to then suggest that it was then hard to define such hypomanic states as ‘abnormal.’ Of those 
voting for the preservation of an impaired functioning criterion, several noted difficulties in 
its operationalising, with suggestions being that it should be more detailed than in DSM-5, 
and probably weighted by severity. Thus, the majority vote arguing for its inclusion was 
respected and proposed definitions will be noted after considering the issue of 
‘hospitalisation.’ 
It was proposed that Criterion C (hospitalisation automatically assigning elevated 
individuals to manic status) be deleted, principally as no other condition is defined by 
hospital status, but also respecting earlier data that hospitalisation does not appear limited to 
those with manic states. Forty-two members were in favour of such deletion, largely on the 
grounds of it being arbitrary as well as subject to local health service practices, insurance, and 
other external factors. Sixteen were in favour of maintaining the hospitalisation criterion, 
generally viewing it as a proxy for severe impairment or, for some, that it allowed mania to 
be diagnosed. Based on such feedback, the recommendation to the Task Force was to delete it 
as an absolute criterion (as employed in DSM-5) but use it as an exemplar of severe 
impairment. 
Returning to impairment, new proposed definitions for mania and hypomania were 
derived. First, for mania: “The mood disturbance is associated with marked impairment in 
functioning, which may be evidenced by the individual not being able to work or not being 
able to interact normally with family and friends, and with such a level of impairment that 
containment strategies including hospitalisation are commonly required.” Second, for 
hypomania: “The mood disturbance may be associated with some level of impairment at 
work and in social functioning, and even need for containment strategies, but generally does 
not prevent the individual from being able to work or interact normally with family and 
friends. Some patients may even report an improvement in functioning in that they are 
genuinely more productive or creative at work.” These definitions position mania as 
distinctly more impairing than hypomania, while an improvement in functioning is conceded 
as possible for some of those with hypomania - as evidenced in the empirical study by Judd et 
al. (2005) - rather than viewing it as an invariably impairing condition. 
In light of concerns about the DSM-5 duration criteria for mania and hypomania 
being too restrictive (in disallowing a bipolar diagnosis in individuals who meet phenotypic 
criteria but who have only brief episodes), Task Force members were asked whether the 
duration criteria should be deleted or preserved and, if in favour of the latter, their 
recommended minimum durations to be imposed were sought. This issue generated greater 
consideration than all other diagnostic nuances. Formally, 49 were in favour of imposing 
duration criteria, most commonly on the basis that deleting a duration criterion would risk 
over-diagnosis of the bipolar disorders in those with normative mood swings or those with 
personality-based emotional dysregulation and thus lead to the bipolar disorders being 
inappropriately diagnosed. Seven were in favour of their deletion, arguing that meeting the 
phenotypic picture should be sufficient. Comments focussed on the difficulty in deciding 
whether to guard against false positive or false negative scenarios, while one offered an 
analogy – that assigning a minimum period was akin to “assigning a minimum duration to a 
hurricane”. For those 36 nominating finite periods, minimum duration recommendations 
ranged from several hours to seven days. The modal recommended minimum duration was 
two days for both mania and hypomania. Many argued that clarification of this criterion 
should be resolved by an empirical study, as will occur. 
Discussion 
The definitions and differentiation of the bipolar disorders remain contentious issues in the 
field of psychiatry (e.g., Fletcher et al., 2018; Malhi and Berk, 2014; Malhi et al., 2016a; 
Malhi et al., 2018), with these issues exacerbated by the many limitations of the DSM and the 
ICD criteria for classifying the bipolar disorders, as detailed in the Introduction. The 
AREDOC Task Force was formed to obtain points of commonality held by those with 
clinical and research expertise in assessing and managing the bipolar disorders so that revised 
criteria could be generated.  
The aim of this paper is to expose readers to limitations of DSM-5 and recent ICD 
definitions, to describe potential corrective strategies that respect the DSM-5 template, and to 
note the degree of consensus by Task Force members in relation to the first-stage revision 
proposal. We detail a set of modified criteria which will be considered and revised by 
members at the second stage of the project. Once relative consensus has been achieved, an 
empirical study will be undertaken to assess the validity of the generated criteria involving 
several hundred putatively diagnosed patients with BP I disorder and BP II disorder as well 
as a group of unipolar depressed subjects. Thus, while those with a bipolar disorder were not 
consulted in this first stage, their views and ratings will be focussed on at the third stage and 
shape many of the final decisions. In addition to the ‘top down’ analytic approach, a ‘bottom 
up’ approach will be employed and, with diagnostic subtype ignored, data from all bipolar 
patients will be analysed (principally by use of a mixture analysis) to determine if manic and 
hypomanic and thus BP I and BP II states can be differentiated categorically rather than 
dimensionally and, if so, the variables that generate such differentiation. Analyses are also 
likely to be iterative in varying the dependent and independent variables to sharpen the 
diagnostic criteria progressively. 
Study patients will complete a structured questionnaire when euthymic that will allow 
testing of all our criteria (and their acceptability and judged validity by the patients). Defining 
constructs (and contributing items) will be derived for both ‘happy’ and ‘snappy’ hypo/manic 
states and ones that differentiate mania from hypomania identified, and cut-off scores 
generated for both the BP I and BP II conditions. Some criteria (especially imposition of 
minimum duration criteria) will be resolved, in part, by analysis of the generated data. If, 
however, a significant percentage of patients do report episodes never lasting more than a 
day, Task Force members will be required to determine how best to address the risk of false 
positive diagnoses, an issue articulated by many of them in respect to several of the 
parameters. 
Overall, by the end of this initiative we hope to have developed and empirically 
derived criteria for defining mania and hypomania that capture quintessential clinical features 
as well as discriminate between manic and hypomanic states. Such criteria will consequently 
assist in distinguishing BP I and BP II states and determining whether this distinction is 
categorical or dimensional, so facilitating future research pursuing differential causes and 
treatments for the bipolar disorders. In exposing the reader to the first phase of this ambitious 
international project, we aimed to provide a persuasive argument for the need to modify 
current DSM-5 and ICD criteria, and capture the views of those with expertise in the bipolar 
disorders on how best to define and classify the two conditions.  
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